Osteoporosis Therapeutics in Asia-Pacific, Industry, Pharmaceutical - for future Market Growth, Challenges, Industrial Demand, Forecast 2016-2025
"Osteoporosis
Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by
Rising Prevalence, Growing Awareness and Expected Launch of Anabolic
Therapies".
The Report covers current Market Trends, Analysis, Forecast, Review,
Share, Size, Growth, Effect.
Description-
Osteoporosis,
the most common metabolic bone disease, is characterized by low bone
mass, microarchitectural deterioration of bone tissue, and a
consequent increase in fracture risk. Osteoporosis is generally known
as an asymptomatic disease, as there are no visible signs until a
fracture occur. In most of the cases, fracture is the clinical
outcome associated with osteoporosis, and it has a complex
pathogenesis that involves trauma to the bone and increased skeletal
fragility. Osteoporosis is a major global public health problem,
associated with significant morbidity, mortality, and socioeconomic
burden. An aging global population will result in an increased number
of people living with the condition, thereby acting as a driver for
revenue growth.
The
osteoporosis market is undergoing a gradual transition from a focus
on antiresorptive therapies to anabolic drug treatment. The market is
set to be driven by recently launched products, and the approval of
drugs that will supplement current market leaders and offer greater
therapeutic options. The marketed products landscape comprises a wide
range of treatment options, including bisphosphonates, SERMs, RANKL
inhibitors, a dual-action non-bisphosphonate (strontium ranelate),
calcitonins and PTH analogues. Nevertheless, significant unmet need
remains for products that can improve bone formation, as well as
effective antiresorptive therapies that offer increased compliance
with few side effects.
Scope
The
osteoporosis Asia-Pacific market will be valued at $7.7 billion in
2022, growing from $4.5 billion in 2015 at a CAGR of 7.8%.
Bisphosphonates
and SERMs dominate the osteoporosis market. However, unmet needs
exist in terms of safety and efficacy. Will the drugs under
development fulfill the unmet needs of the osteoporosis market?
How
will immunotherapies such as Prolia contribute to growth?
What
effect will the patent expirations of currently branded therapies
have on market value?
The
pipeline contains a range of molecule types and molecular targets,
including those that are well established in osteoporosis, and novel,
first-in-class therapies.
Which
molecular targets appear most frequently in the pipeline?
Is
there strong potential for the pipeline to address unmet needs within
the osteoporosis market?
Will
the pipeline address unmet needs related to limited anabolic
therapies for osteoporosis patients?
The
market forecasts indicate that Japan will contribute the most to the
Asia-Pacific market value, due to the emergence of novel therapies.
How
will the annual cost of therapy and market size vary between the five
Asia-Pacific markets?
How
could changes in risk factors such as aging population, calcium and
vitamin D deficiency influence the market?
Various
drivers and barriers will influence the market over the forecast
period.
What
are the barriers that limit the uptake of premium-priced therapeutics
in the assessed countries?
Which
factors are most likely to drive the market in these countries?
Reasons
to buy
This
report will allow you to -
Understand
the current clinical and commercial landscape by considering disease
pathogenesis, diagnosis, prognosis, and the treatment options
available at each stage of diagnosis, including a clinical comparison
of marketed therapies.
For
More Information Kindly Contact:
ResearchMoz
Global Pvt. Ltd.
90
State Street,
Albany,
NY 12207,
United
States
Blog
- http://bit.ly/2b1Ayn6
866-997-4948
(Us-Canada Toll Free),
+1-518-621-2074,
Email
to:
sales@researchmoz.us,
Comments
Post a Comment